KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Share-based Compensation (2016 - 2025)

AbbVie (ABBV) has disclosed Share-based Compensation for 14 consecutive years, with $157.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 4.27% to $157.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $955.0 million through Dec 2025, up 4.83% year-over-year, with the annual reading at $955.0 million for FY2025, 4.83% up from the prior year.
  • Share-based Compensation for Q4 2025 was $157.0 million at AbbVie, down from $209.0 million in the prior quarter.
  • The five-year high for Share-based Compensation was $410.0 million in Q1 2025, with the low at $107.0 million in Q2 2022.
  • Average Share-based Compensation over 5 years is $198.8 million, with a median of $171.5 million recorded in 2023.
  • The sharpest move saw Share-based Compensation tumbled 32.7% in 2022, then skyrocketed 67.29% in 2023.
  • Over 5 years, Share-based Compensation stood at $129.0 million in 2021, then increased by 2.33% to $132.0 million in 2022, then fell by 5.3% to $125.0 million in 2023, then surged by 31.2% to $164.0 million in 2024, then dropped by 4.27% to $157.0 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $157.0 million, $209.0 million, and $179.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.